Click here to view our pitch deck.

Why Eliaz Therapeutics?

We’re honored to announce that the FDA has awarded XGal-3® its Breakthrough Device Designation!

In the medical world, this designation is highly coveted for many reasons.

It validates technologies that address urgent, unmet medical needs. It gives patients timely access to innovative treatments that are highly vetted for safety and effectiveness. And often, it offers hope where there is none.

At Eliaz Therapeutics, achieving this milestone represents decades of intensive research coming to fruition. But for our supporters and investors, it represents a tremendous opportunity to help address one of medicine’s most urgent challenges.

For over three decades, I've dedicated my life to innovating healthcare solutions that alleviate human suffering. This journey led me to develop Pectosol, a natural Galectin-3 blocker backed by nearly 100 research papers, and build a community of over 300,000 health enthusiasts through my integrative medicine work.

The tragic loss of my father to immune dysregulation underlying sepsis ignited a personal mission to combat inflammatory conditions. This led to the creation of XGal-3®, a groundbreaking device designed to halt sepsis progression by targeting Galectin-3, a protein driving the deadly inflammatory process.

Our patented technology, supported by 2 prestigious NIH grants and protected by over 60 patents across 34 countries, has the potential to stop sepsis within hours. With our world-class team, we've developed a working prototype and are rapidly advancing towards clinical trials.

Back in 2023, ecoNugenics, my previous venture, was successfully acquired by a prestigious private equity company, demonstrating our team's ability to create and realize the value in the healthcare sector.

Now, as an investor in Eliaz Therapeutics, you have the opportunity to support a movement—one with the potential to save millions of lives across the world.

I sincerely hope you join us in the fight against sepsis.

Invest in Eliaz Therapeutics today!

Sepsis is a Silent Killer That Claims 11 Million Lives Annually

Sepsis strikes without warning, claiming a life every 2.8 seconds. Despite its devastating impact, it remains largely overlooked in public health discussions. This silent killer turns routine infections into catastrophic bodily responses, leading to rapid organ failure and death.

Throughout my career, I've witnessed sepsis devastate countless patients and families. This deadly condition imposes a staggering $62 billion annual burden on the U.S. healthcare system. Current treatments only manage symptoms, neglecting the root cause of sepsis. There is no effective therapy targeting the underlying inflammatory process. Our groundbreaking research at Eliaz Therapeutics aims to change this paradigm, offering hope where none existed before.

WHEN GOOD PROTEINS GO ROGUE

Galectin-3 is a key driver of sepsis when released into the bloodstream. During sepsis and acute kidney injury (AKI), it triggers a cascade of harmful effects.

EFFECTS OF GALECTIN-3 IN SEPSIS AND AKI

1. Inflammation
2. Disease progression
3. Organ fibrosis
4. Increased morbidity and mortality

DISEASES ASSOCIATED WITH GALECTIN-3:

• Sepsis
• Kidney diseases (AKI, CKD)
• Heart disease
• Liver cirrhosis
• Cancer  
• Pulmonary hypertension
• Stroke
• Diabetes
• Autoimmune diseases
• Neuroinflammatory diseases

Introducing XGal-3®: A New Hope for Sepsis Patients

XGal-3® is a medical device that works like dialysis but with a crucial difference. Using proprietary anti-Galectin-3 antibody traps, it targets and removes Galectin-3 from the bloodstream, potentially halting sepsis progression. By disrupting the pathological cascade, XGal-3® aims to prevent the devastating inflammatory cascade and organ damage, and save lives. This targeted approach tackles the root cause of sepsis, offering new hope for millions. 

HOW IT WORKS:

1. We connect the patient to XGal-3® using standard IV lines
2. Blood flows through our device and is separated into plasma and cellular components
3. XGal-3® removes the harmful Galectin-3 protein from the plasma
4. The cleansed blood returns to the patient
5. The whole process takes just hours, potentially saving the patient's life

From Concept to Breakthrough

• Created XGal-3® prototype: A first-of-its-kind sepsis treatment
• Protected innovation: 60+ patents in 34 countries
• Validated by NIH: Secured 2 research grants
• Partnered with Terumo: Global leader in medical apheresis technology
• Expanded collaborations: Teamed with a multi-billion dollar diagnostics leader

A $1.97 Trillion Global Market Desperate for Innovation

XGal-3® targets a massive $1.97 trillion global market. Our vision is to:

• Transform the treatment for inflammatory and fibrotic diseases
• Save & improve millions of lives worldwide
• Start with sepsis, then expand to broader applications

OUR STRATEGY:

1. Target Septic Shock First: Address the urgent unmet need in ICUs, where mortality rates can reach up to 60%
2. Strategic Relationships: Collaborate with global apheresis leader for rapid hospital adoption
3. Maximize Distribution: Partner with distributors, Group Purchasing Organizations, and hospital networks for widespread adoption
4. Diversify Revenue: Combine direct sales with strategic licensing opportunities
5. Expand Applications: Explore XGAL-3®'s potential in AKI, chronic kidney disease, cancer, and fibrosis

Our Team is Led by World-Class Experts from Stanford, Mayo Clinic, and leading Biotech Companies

I'm incredibly proud of the team we've assembled at Eliaz Therapeutics. We've come together from diverse backgrounds in medicine, research, and business, but we're united by a deep commitment to making a difference in the lives of millions. 

The Perfect Storm

We’re at a critical juncture: 

• COVID-19 highlighted the urgent need for effective sepsis treatments
• Medical community more open to innovative approaches
• Our working prototype is ready for clinical trials
• The global sepsis treatment market is projected to grow due to aging populations and increasing chronic disease prevalence

Together, We Can Bring X-Gal-3® to Market and Save Millions of Lives

By investing in Eliaz Therapeutics, you're helping us turn "goodbye" into "welcome home" for families around the world. Let’s defeat sepsis by making XGal-3® standard equipment in every ICU, saving lives daily. 

Your investment directly supports:

• Completing crucial safety and efficacy trials with the FDA to bring XGal-3® to market.
• Bringing hope to millions facing sepsis and other life-threatening conditions
• Revolutionizing the way sepsis and other conditions are treated in hospitals around the world.